CA Patent

CA2540225A1 — Solid preparation of pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester

Assigned to Takeda Pharmaceutical Co Ltd · Expires 2005-05-12 · 21y expired

What this patent protects

A solid preparation useful as a diabetes-treating agent or the like and excellent in the dissolution properties of an insulin sensitizer and an insulin secretagogue, which comprises an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester is …

USPTO Abstract

A solid preparation useful as a diabetes-treating agent or the like and excellent in the dissolution properties of an insulin sensitizer and an insulin secretagogue, which comprises an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester is provided. In an embodiment, there is provided a solid preparation comprising a layer containing pioglitazone or a salt thereof; and a layer containing glimepiride and a polyoxyethylene sorbitan fatty acid ester.

Drugs covered by this patent

Patent Metadata

Patent number
CA2540225A1
Jurisdiction
CA
Classification
—
Expires
2005-05-12
Drug substance claim
No
Drug product claim
No
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.